Dramatic advances in retinal imaging technology over the last two decades have significantly improved our understanding of the natural history and pathophysiology of non-neovascular age-related macular degeneration(AM...Dramatic advances in retinal imaging technology over the last two decades have significantly improved our understanding of the natural history and pathophysiology of non-neovascular age-related macular degeneration(AMD).Currently,aside from micronutrient supplements,there are no proven treatments for non-neovascular or dry AMD.Recently,a number of pharmacological agents have been evaluated or are under evaluation for treatment of patients with end-stage dry AMD manifesting as geographic atrophy(GA).It may preferable,however,to intervene earlier in the disease before the development of irreversible loss of visual function.Earlier intervention would require a more precise understanding of biomarkers which may increase the risk of progression from early and intermediate stages to the late stage of the disease.The development of optical coherence tomography angiography(OCTA)has allowed the layers of the retinal microcirculation and choriocapillaris(CC)to be visualized and quantified.Flow deficits in the CC have been observed to increase with age,particularly centrally,and these flow deficits appear to worsen with development and progression of AMD.As such,OCTA-based CC assessment appears to be a valuable new biomarker in our assessment and risk-stratification of AMD.Alterations in the CC may also provide new insights into the pathophysiology of the disease.Enhancement of choriocapillaris function may also prove to be a target of future therapeutic strategies or as a biomarker to monitor the effectiveness of therapy.As such,CC imaging may be anticipated to be an integral tool in the management of dry AMD.展开更多
文摘Dramatic advances in retinal imaging technology over the last two decades have significantly improved our understanding of the natural history and pathophysiology of non-neovascular age-related macular degeneration(AMD).Currently,aside from micronutrient supplements,there are no proven treatments for non-neovascular or dry AMD.Recently,a number of pharmacological agents have been evaluated or are under evaluation for treatment of patients with end-stage dry AMD manifesting as geographic atrophy(GA).It may preferable,however,to intervene earlier in the disease before the development of irreversible loss of visual function.Earlier intervention would require a more precise understanding of biomarkers which may increase the risk of progression from early and intermediate stages to the late stage of the disease.The development of optical coherence tomography angiography(OCTA)has allowed the layers of the retinal microcirculation and choriocapillaris(CC)to be visualized and quantified.Flow deficits in the CC have been observed to increase with age,particularly centrally,and these flow deficits appear to worsen with development and progression of AMD.As such,OCTA-based CC assessment appears to be a valuable new biomarker in our assessment and risk-stratification of AMD.Alterations in the CC may also provide new insights into the pathophysiology of the disease.Enhancement of choriocapillaris function may also prove to be a target of future therapeutic strategies or as a biomarker to monitor the effectiveness of therapy.As such,CC imaging may be anticipated to be an integral tool in the management of dry AMD.
